Dermatology Times

JULY 10, 2024

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, have a comprehensive discussion on treatment safety considerations for patients with atopic dermatitis who are breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

Dermatology Times

JUNE 10, 2024

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Safety 73

Safety Treatments Dermatitis 73

Dermatology Times

JULY 8, 2024

Robert Bruce Posnick, MD, examines a case of a 55-year-old female patient with a 50-year history of atopic dermatitis, comorbid asthma, and severe alopecia areata, presenting with recurrent patches throughout her body, predominantly affecting her face, hands, trunk, arms, legs, and eyelids.

Dermatitis 36

Dermatitis Safety Management Treatments 36

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

Dermatology Times

JUNE 12, 2024

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dermatitis 36

Dermatitis Treatments Safety 36

Dermatology Times

AUGUST 24, 2023

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

AUGUST 25, 2023

Christopher Bunick, MD, PhD, discusses a novel tool to visualize key safety results of Janus kinase inhibitors in treating patients with atopic dermatitis.

Safety 36

Safety Dermatitis Tools 36

Dermatology Times

AUGUST 16, 2023

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

AUGUST 9, 2023

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

JULY 19, 2024

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

Safety 45

Safety Dermatitis 45

Dermatology Times

OCTOBER 3, 2023

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

Dermatitis 36

Dermatitis Treatments Safety Dermatology 36

Dermatology Times

DECEMBER 11, 2023

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Safety 74

Safety Management Dermatitis 74

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

Dermatology Times

MAY 13, 2024

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

Safety 74

Safety Dermatitis Treatments 74

First Derm

AUGUST 25, 2023

However, it is important to address the misconception that “natural” automatically equates to safety. By addressing the misconception surrounding the safety of natural skin care products, we can better understand the need for careful evaluation and consideration when choosing these products.

Dermatitis 40

Dermatitis Irritation Skincare Sensitive Skin 40

Dermatology Times

DECEMBER 18, 2023

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

Safety 74

Safety Dermatitis 74

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

Dermatology Times

JANUARY 11, 2024

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Safety 73

Safety Dermatitis 73

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. It is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. in seborrheic dermatitis. in seborrheic dermatitis.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

JANUARY 14, 2024

People with seborrheic dermatitis who don’t use topical steroids are 3.5 Zoryve foam is a once-daily steroid-free topical for use in all skin and hair types that effectively clears and controls seborrheic dermatitis. Food and Drug Administration (FDA) approved topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis.

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). The dotted red line in the ladder represents the boundary between safer therapies and systemic treatments with more significant safety risks. The study appears in Dermatitis.

Treatments 77

Treatments Dermatitis Therapy Safety 77

The Dermatology Digest

JULY 19, 2024

Limiting the use of oral corticosteroid treatment to 90 days or less may limit adverse effects in patients with atopic dermatitis (AD). This is the main takeaway from a new nested case-control study in JAMA Network Open that looked at the long-term use of oral corticosteroids and safety outcomes for AD patients.

Dermatitis 36

Dermatitis Networking Safety Dermatology 36

Dermatology Times

OCTOBER 16, 2023

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

Dermatitis 68

Dermatitis Safety 68

Dermatology Times

JUNE 19, 2024

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Treatments 36

Treatments Dermatitis Safety Clinic 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. “It is important to have systemic treatments approved for CHE, both with and without atopic dermatitis. . and Sanofi report. “We

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

FEBRUARY 14, 2024

and is the same strength and formulation studied in the ADORING Phase 3 development program and included in the sNDA submission for atopic dermatitis. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. No new safety signals were observed with long-term use. Fully 80.7%

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

AUGUST 13, 2024

Drawing upon their 2016 discovery that the interferon response is constantly activated in people with Down syndrome, researchers designed the trial to focus on the autoimmune and inflammatory skin conditions that are common in people with Down syndrome including alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa.

Clinic 74

Clinic Safety Dermatitis Medical 74

The Dermatology Digest

APRIL 30, 2024

Eli Lilly has resubmitted its Biologics License Application (BLA) for Lebrikizumab for the treatment of moderate to severe atopic dermatitis (AD), with regulatory action anticipated in the second half of 2024. There were no concerns with lebrikizumab’s clinical data package, safety, or label.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab. The National Institute for Health and Care Excellence (NICE) now recommends lebrikizumab (Ebglyss, Almirall S.A.)

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

MARCH 10, 2024

More than two-thirds of people with atopic dermatitis (AD) and darker skin tones treated with lebrikizumab showed improvements in skin clearance and itch relief, according to late-breaking results from a Phase 3 study are being presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

JANUARY 23, 2024

Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis.

Dermatitis 36

Dermatitis Safety Sustainability Eczema 36

The Dermatology Digest

JUNE 14, 2024

Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.

Dermatitis 36

Dermatitis Marketing Innovations Safety 36